Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 128 of the 131 references it cites were found in a registry or an index.

Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia

Memel, Zoe, Gold, Stephanie L., Pearlman, Michelle, Muratore, Alicia, Martindale, Robert · 2025 · Current Nutrition Reports

Abstract

Purpose of review Glucagon-like peptide- 1 receptor agonists (GLP- 1 RA) are a rapidly expanding class of medications used to treat many chronic diseases. This review explores factors that may contribute to accelerated muscle loss among higher-risk patient populations and describes tailored interventions to reduce the risk of accelerated sarcopenia and frailty. Recent findings While GLP- 1 RA can result in total weight loss upwards of 25%, recent studies show that they can also lead to significant loss of lean body mass, reaching as high as 15-40% of total weight lost. This rapid and significant decline in muscle mass while taking GLP- 1 RA places certain patient populations already predisposed to sarcopenia at higher risk for muscle loss and adverse events. Currently, there is insufficient evidence delving into the impact of GLP- 1 RA on body composition among older adults, patients with chronic kidney disease, liver disease, and inflammatory bowel disease. However, research suggests that a high protein diet and resistance training may help prevent loss of muscle mass during GLP- 1 RA usage. A targeted and individualized nutrition and physical activity regimen should be instituted for each patient with a focus on optimizing protein intake and performing frequent resistance training in order to minimize loss of muscle mass while promoting the loss of fat mass. Future research should evaluate the impact of GLP- 1 RA on sarcopenia in high-risk patient populations.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13668-025-00649-w

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 131 references

Research works printed but not linked: 2

  1. Institute of Medicine. Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: The National Academies Press; 2005. https://nap.nationalacademies.org/catalog/10490/dietaryreference-intakes-for-energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids.
  2. Wilding JPH, Calanna S, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. Reply N Engl J Med. 2021;385(1):e4.

Cited by

See all 64

Metadata

Authors
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R.
Affiliations
  • University of California, San Francisco (US)
  • Mount Sinai Hospital (US)
  • University of North Carolina at Chapel Hill (US)
  • Oregon Health & Science University (US)
Corresponding author
Martindale, Robert
Venue
Current Nutrition Reports
Published
2025-04-28
Volume
14
Issue
1
Pages
63-63
ISSN
2161-3311 (ISSN-L)
OpenAlex
W4409857710
Cited by
63
References
131
Citations by year
2026: 47 · 2025: 17
FWCI
32.92
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Nutrition Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
GLP-1 receptor agonists, sarcopenia, muscle mass loss, lean body mass, frailty, weight loss, body composition, high-protein diet
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Body Composition, Humans, Hypoglycemic Agents, Risk Factors, Weight Loss, Muscle, Skeletal, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. https://app.cochat.ai/papers/10.1007/s13668-025-00649-w
The paper
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R. (2025). Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. Current Nutrition Reports. https://doi.org/10.1007/s13668-025-00649-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.